1.90
1.90 (0%)
As of Sep 24, 2024
Opgen Inc [OPGN]
Source:
Company Overview
OpGen operated as a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. The Company, along with its subsidiaries, Curetis and Ares Genetics, developed and commercialized molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs.
| Country | United States |
| Headquarters | rockville, maryland |
| Phone Number | 301-869-9683 |
| Industry | services |
| CEO | David E. Lazar |
| Website | www.opgen.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-0.8 |
| Net Income | $8.9 |
| Net Cash | $0.5 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | 326.6% |
| Profit as % of Stockholder Equity | 299.1% |
Management Effectiveness
| Return on Equity | 299.1% |
| Return on Assets | 163.3% |
| Turnover Ratio | |
| EBITA | $-0.8 |
Balance Sheet and Cash Flow Measures
| Total Assets | $5.5 |
| Total Liabilities | $2.5 |
| Operating Cash Flow | $-4.6 |
| Investing Cash Flow | $0 |
| Financing Cash Flow | $5.1 |
